Raras
Buscar doenças, sintomas, genes...
Alteração de glicosilação múltipla
ORPHA:309526CID-11 · 5C54.2DOENÇA RARA

Ciclo-oxigenase-1 (COX-1) também conhecida como prostaglandin G/H synthase 1, prostaglandin-endoperoxide synthase 1 ou prostaglandin H2 synthase 1 é uma enzima que em humanos é codificada pelo gene PTGS1. É responsável pela catálise de prostaglandinas e tromboxano. Possui função fisiológica constitutiva e participa de uma série de processos de manutenção dos processos do organismo como a proteção da mucosa gástrica, hemostasia e regulação de perfusão renal.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Doença genética rara que afeta a glicosilação de proteínas, resultando em fibrose hepática, infecções respiratórias recorrentes e alterações neurológicas. Pode apresentar linfoma, síndrome nefrótica transitória e cabelo espesso.

🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
83 sintomas
🦴
Ossos e articulações
55 sintomas
💪
Músculos
39 sintomas
😀
Face
35 sintomas
🧬
Pele e cabelo
28 sintomas
🫃
Digestivo
27 sintomas

+ 223 sintomas em outras categorias

Características mais comuns

Fibrose hepática
Infecções respiratórias recorrentes
Síndrome nefrótica transitória
Linfoma
Endopoliploidia em estudos cromossômicos da medula óssea
Morfologia anormal da substância branca cerebral
636sintomas
Sem dados (636)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 636 características clínicas mais associadas, ordenadas por frequência.

Fibrose hepáticaHepatic fibrosis
Infecções respiratórias recorrentesRecurrent respiratory infections
Síndrome nefrótica transitóriaTransient nephrotic syndrome
LinfomaLymphoma
Endopoliploidia em estudos cromossômicos da medula ósseaEndopolyploidy on chromosome studies of bone marrow

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa2
Últimos 10 anos200publicações
Pico2025145 papers
Linha do tempo
2024Hoje · 2026🧪 2018Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

23 genes identificados com associação a esta condição.

COG6Conserved oligomeric Golgi complex subunit 6Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for normal Golgi function

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (2)
COPI-mediated anterograde transportIntra-Golgi traffic
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2L

A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. Clinical features of CDG2L include neonatal intractable focal seizures, vomiting, loss of consciousness, intracranial bleeding due to vitamin K deficiency, and death in infancy.

OUTRAS DOENÇAS (2)
hypohidrosis-enamel hypoplasia-palmoplantar keratoderma-intellectual disability syndromeCOG6-congenital disorder of glycosylation
HGNC:18621UniProt:Q9Y2V7
SLC35C1GDP-fucose transporter 1Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Antiporter specific for GDP-l-fucose and depending on the concomitant reverse transport of GMP. Involved in GDP-fucose import from the cytoplasm into the Golgi lumen

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (2)
Transport of nucleotide sugarsGDP-fucose biosynthesis
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2C

A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. The clinical features of CDG2C include intellectual disability, short stature, facial stigmata, and recurrent bacterial peripheral infections with persistently elevated peripheral leukocytes. Biochemically, CDG2C is characterized by a lack of fucosylated glycoconjugates, including selectin ligands.

EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Mucosa
50.7 TPM
Fígado
45.0 TPM
Glândula salivar
35.6 TPM
Tecido adiposo
28.5 TPM
Fibroblastos
28.4 TPM
OUTRAS DOENÇAS (1)
leukocyte adhesion deficiency type II
HGNC:20197UniProt:Q96A29
COG8Conserved oligomeric Golgi complex subunit 8Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for normal Golgi function

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (2)
COPI-mediated anterograde transportIntra-Golgi traffic
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2H

CDGs are a family of severe inherited diseases caused by a defect in protein N-glycosylation. They are characterized by under-glycosylated serum proteins. These multisystem disorders present with a wide variety of clinical features, such as disorders of the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

OUTRAS DOENÇAS (1)
COG8-congenital disorder of glycosylation
HGNC:18623UniProt:Q96MW5
VMA22Vacuolar ATPase assembly protein VMA22Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Accessory component of the proton-transporting vacuolar (V)-ATPase protein pump involved in intracellular iron homeostasis. In aerobic conditions, required for intracellular iron homeostasis, thus triggering the activity of Fe(2+) prolyl hydroxylase (PHD) enzymes, and leading to HIF1A hydroxylation and subsequent proteasomal degradation. Necessary for endolysosomal acidification and lysosomal degradation (PubMed:28296633). May be involved in Golgi homeostasis (PubMed:26833332)

LOCALIZAÇÃO

EndosomeLysosomeEndoplasmic reticulum-Golgi intermediate compartmentCytoplasmic vesicle, COPI-coated vesicleEndoplasmic reticulum

VIAS BIOLÓGICAS (1)
RHOA GTPase cycle
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2O

A form of congenital disorder of glycosylation, a genetically heterogeneous group of autosomal recessive, multisystem disorders caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. CDG2O is characterized by hepatosplenomegaly, liver failure, hypotonia, and psychomotor disability.

VIAS REACTOME (1)
OUTRAS DOENÇAS (1)
CCDC115-CDG
HGNC:28178UniProt:Q96NT0
GNEBifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Bifunctional enzyme that possesses both UDP-N-acetylglucosamine 2-epimerase and N-acetylmannosamine kinase activities, and serves as the initiator of the biosynthetic pathway leading to the production of N-acetylneuraminic acid (NeuAc), a critical precursor in the synthesis of sialic acids. By catalyzing this pivotal and rate-limiting step in sialic acid biosynthesis, this enzyme assumes a pivotal role in governing the regulation of cell surface sialylation, playing a role in embryonic angiogene

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Sialic acid metabolism
MECANISMO DE DOENÇA

Sialuria

In sialuria, free sialic acid accumulates in the cytoplasm and gram quantities of neuraminic acid are secreted in the urine. The metabolic defect involves lack of feedback inhibition of UDP-GlcNAc 2-epimerase by CMP-Neu5Ac, resulting in constitutive overproduction of free Neu5Ac. Clinical features include variable degrees of developmental delay, coarse facial features and hepatomegaly. Sialuria inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
33.4 TPM
Glândula salivar
24.0 TPM
Cérebro - Hemisfério cerebelar
23.1 TPM
Cólon transverso
21.3 TPM
Ovário
21.0 TPM
OUTRAS DOENÇAS (4)
GNE myopathysialuriathrombocytopenia 12 with or without myopathyplatelet-type bleeding disorder 19
HGNC:23657UniProt:Q9Y223
COG5Conserved oligomeric Golgi complex subunit 5Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for normal Golgi function

LOCALIZAÇÃO

Cytoplasm, cytosolGolgi apparatus membrane

VIAS BIOLÓGICAS (2)
COPI-mediated anterograde transportIntra-Golgi traffic
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2I

A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. Congenital disorder of glycosylation type 2I is characterized by mild neurological impairments.

OUTRAS DOENÇAS (1)
COG5-congenital disorder of glycosylation
HGNC:14857UniProt:Q9UP83
B4GALT1Beta-1,4-galactosyltransferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Galactosyltransferase acting in the Golgi stacks. Catalyzes the transfer of galactose (Gal) from UDP-alpha-D-galactose in beta(1->4) linkage to the non-reducing terminal N-acetylglucosamine (GlcNAc) moieties of glycolipids and complex-type N-linked glycans (PubMed:16157350, PubMed:27872474, PubMed:29133956, PubMed:36280670, PubMed:37632720, PubMed:38321209). Adds one Gal residue to both GlcNAc beta(1->2)-linked to the alpha(1->3) and alpha(1->6) mannose antennae of complex-type N-glycans, enabli

LOCALIZAÇÃO

Golgi apparatus, Golgi stack membraneCell membraneCell surfaceCell projection, filopodiumSecreted

VIAS BIOLÓGICAS (4)
Pre-NOTCH Processing in GolgiKeratan sulfate biosynthesisN-Glycan antennae elongationLactose synthesis
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2D

A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

OUTRAS DOENÇAS (2)
combined low LDL and fibrinogenB4GALT1-congenital disorder of glycosylation
HGNC:924UniProt:P15291
CADDNA fragmentation factor subunit betaDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Nuclease that induces DNA fragmentation and chromatin condensation during apoptosis. Degrades naked DNA and induces apoptotic morphology

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
Pyrimidine biosynthesis
OUTRAS DOENÇAS (1)
developmental and epileptic encephalopathy, 50
HGNC:1424UniProt:O76075
DPM3Dolichol-phosphate mannosyltransferase subunit 3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Stabilizer subunit of the dolichol-phosphate mannose (DPM) synthase complex; tethers catalytic subunit DPM1 to the endoplasmic reticulum

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (4)
Synthesis of dolichyl-phosphate mannoseMaturation of DENV proteinsDefective DPM1 causes DPM1-CDGDefective DPM2 causes DPM2-CDG
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with impaired intellectual development B15

An autosomal recessive, congenital muscular disorder characterized by hyperCKemia, myopathic features observed on muscle biopsy, developmental delay, mildly impaired intellectual development with learning difficulties, epilepsy, and mild white matter abnormalities.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
101.0 TPM
Tireoide
86.4 TPM
Útero
85.8 TPM
Cervix Endocervix
81.3 TPM
Fallopian Tube
79.3 TPM
OUTRAS DOENÇAS (2)
DPM3-congenital disorder of glycosylationmuscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type B, 15
HGNC:3007UniProt:Q9P2X0
DPM2Dolichol phosphate-mannose biosynthesis regulatory proteinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Regulates the biosynthesis of dolichol phosphate-mannose (PubMed:10835346). Regulatory subunit of the dolichol-phosphate mannose (DPM) synthase complex; essential for the ER localization and stable expression of DPM1 (PubMed:10835346). Part of the glycosylphosphatidylinositol-N-acetylglucosaminyltransferase (GPI-GnT) complex that catalyzes the transfer of N-acetylglucosamine from UDP-N-acetylglucosamine to phosphatidylinositol and participates in the first step of GPI biosynthesis (PubMed:161628

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (5)
Synthesis of dolichyl-phosphate mannoseMaturation of DENV proteinsDefective DPM3 causes DPM3-CDGDefective DPM1 causes DPM1-CDGSynthesis of glycosylphosphatidylinositol (GPI)
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1U

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. Some CDG1U patients have dystrophic changes seen on muscle biopsy and reduced O-mannosyl glycans on alpha-dystroglycan.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
86.9 TPM
Fibroblastos
64.0 TPM
Próstata
61.1 TPM
Cervix Endocervix
59.8 TPM
Cervix Ectocervix
57.1 TPM
OUTRAS DOENÇAS (1)
congenital muscular dystrophy with intellectual disability and severe epilepsy
HGNC:3006UniProt:O94777
COG1Conserved oligomeric Golgi complex subunit 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for normal Golgi function

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (2)
COPI-mediated anterograde transportIntra-Golgi traffic
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2G

A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. Clinical features of CDG2G include failure to thrive, generalized hypotonia, growth retardation and mild psychomotor retardation. CDG2G is biochemically characterized by a defect in O-glycosylation as well as N-glycosylation.

OUTRAS DOENÇAS (1)
COG1-congenital disorder of glycosylation
HGNC:6545UniProt:Q8WTW3
COG7Conserved oligomeric Golgi complex subunit 7Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for normal Golgi function

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (2)
COPI-mediated anterograde transportIntra-Golgi traffic
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2E

A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

OUTRAS DOENÇAS (1)
COG7-congenital disorder of glycosylation
HGNC:18622UniProt:P83436
COG4Conserved oligomeric Golgi complex subunit 4Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for normal Golgi function (PubMed:19536132, PubMed:30290151). Plays a role in SNARE-pin assembly and Golgi-to-ER retrograde transport via its interaction with SCFD1 (PubMed:19536132)

LOCALIZAÇÃO

Cytoplasm, cytosolGolgi apparatus membrane

VIAS BIOLÓGICAS (2)
COPI-mediated anterograde transportIntra-Golgi traffic
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2J

A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

OUTRAS DOENÇAS (2)
microcephalic osteodysplastic dysplasia, Saul-Wilson typeCOG4-congenital disorder of glycosylation
HGNC:18620UniProt:Q9H9E3
SEC23BProtein transport protein Sec23BDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the coat protein complex II (COPII) which promotes the formation of transport vesicles from the endoplasmic reticulum (ER). The coat has two main functions, the physical deformation of the endoplasmic reticulum membrane into vesicles and the selection of cargo molecules for their transport to the Golgi complex

LOCALIZAÇÃO

Cytoplasmic vesicle, COPII-coated vesicle membraneEndoplasmic reticulum membraneCytoplasm, cytosol

MECANISMO DE DOENÇA

Cowden syndrome 7

A form of Cowden syndrome, a hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. CWS7 inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
79.2 TPM
Pituitária
53.5 TPM
Testículo
43.3 TPM
Glândula adrenal
42.8 TPM
Glândula salivar
37.9 TPM
OUTRAS DOENÇAS (3)
congenital dyserythropoietic anemia type 2Cowden syndrome 7Cowden disease
HGNC:10702UniProt:Q15437
PGM3Phosphoacetylglucosamine mutaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the conversion of GlcNAc-6-P into GlcNAc-1-P during the synthesis of uridine diphosphate/UDP-GlcNAc, a sugar nucleotide critical to multiple glycosylation pathways including protein N- and O-glycosylation

LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
Synthesis of UDP-N-acetyl-glucosamine
MECANISMO DE DOENÇA

Immunodeficiency 23

A primary immunodeficiency syndrome characterized by recurrent respiratory and skin infections beginning in early childhood, severe atopy, increased serum IgE, and developmental delay or cognitive impairment of varying severity.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
41.8 TPM
Pituitária
34.3 TPM
Próstata
27.8 TPM
Ovário
24.5 TPM
Cervix Endocervix
22.3 TPM
OUTRAS DOENÇAS (1)
immunodeficiency 23
HGNC:8907UniProt:O95394
SLC35A2UDP-galactose translocatorDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Transports uridine diphosphate galactose (UDP-galactose) from the cytosol into the Golgi apparatus, functioning as an antiporter that exchanges UDP-galactose for UMP (PubMed:12682060, PubMed:9010752). It is also able to exchange UDP-galactose for AMP and CMP, and to transport UDP-N-acetylgalactosamine (UDP-GalNAc) and other nucleotide sugars (PubMed:11784306, PubMed:12682060). As a provider of UDP-galactose to galactosyltransferases present in the Golgi apparatus, it is necessary for globotriaos

LOCALIZAÇÃO

Endoplasmic reticulum membraneGolgi apparatus membrane

VIAS BIOLÓGICAS (1)
Transport of nucleotide sugars
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2M

An X-linked dominant, severe neurologic disorder characterized by developmental delay, hypotonia, ocular anomalies, and brain malformations. Othere more variable clinical features included seizures, hypsarrhythmia, poor feeding, microcephaly, recurrent infections, dysmorphic features, shortened limbs, and coagulation defects. Congenital disorders of glycosylation are caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins and a wide variety of clinical features. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
22.3 TPM
Pituitária
20.4 TPM
Esôfago - Mucosa
16.9 TPM
Pulmão
16.7 TPM
Glândula salivar
16.6 TPM
OUTRAS DOENÇAS (2)
SLC35A2-congenital disorder of glycosylationisolated focal cortical dysplasia type Ia
HGNC:11022UniProt:P78381
COG2Conserved oligomeric Golgi complex subunit 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for normal Golgi morphology and function

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (2)
COPI-mediated anterograde transportIntra-Golgi traffic
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2Q

A form of congenital disorder of glycosylation, a genetically heterogeneous group of autosomal recessive, multisystem disorders caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. The transmission pattern of CDG2Q is consistent with autosomal recessive inheritance.

OUTRAS DOENÇAS (1)
congenital disorder of glycosylation, type IIq
HGNC:6546UniProt:Q14746
DOLKDolichol kinaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes CTP-mediated phosphorylation of dolichol, the terminal step in de novo dolichyl monophosphate (Dol-P) biosynthesis (PubMed:12213788, PubMed:16923818, PubMed:17273964, PubMed:22242004). Dol-P is a lipid carrier essential for the synthesis of N-linked and O-linked oligosaccharides and for GPI anchors (PubMed:12213788)

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Synthesis of dolichyl-phosphate
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1M

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. CDG1M is a very severe disease with death occurring in early life.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
35.3 TPM
Fibroblastos
32.5 TPM
Glândula adrenal
23.3 TPM
Útero
18.7 TPM
Cervix Endocervix
18.5 TPM
OUTRAS DOENÇAS (2)
DK1-congenital disorder of glycosylationfamilial isolated dilated cardiomyopathy
HGNC:23406UniProt:Q9UPQ8
DPM1Dolichol-phosphate mannosyltransferase subunit 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Transfers mannose from GDP-mannose to dolichol monophosphate to form dolichol phosphate mannose (Dol-P-Man) which is the mannosyl donor in pathways leading to N-glycosylation, glycosyl phosphatidylinositol membrane anchoring, and O-mannosylation of proteins; catalytic subunit of the dolichol-phosphate mannose (DPM) synthase complex

LOCALIZAÇÃO

Endoplasmic reticulum

VIAS BIOLÓGICAS (4)
Synthesis of dolichyl-phosphate mannoseMaturation of DENV proteinsDefective DPM3 causes DPM3-CDGDefective DPM2 causes DPM2-CDG
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1E

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. Some CDG1E patients have features consistent with a dystroglycanopathy and congenital muscular dystrophy, including O-mannosylation defect, camptodactyly, elevated creatine kinase, motor delay and dystrophic changes on muscel biopsy.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
94.4 TPM
Fibroblastos
90.2 TPM
Testículo
78.2 TPM
Útero
70.8 TPM
Cervix Ectocervix
68.1 TPM
OUTRAS DOENÇAS (1)
congenital disorder of glycosylation type 1E
HGNC:3005UniProt:O60762
VMA12Vacuolar ATPase assembly protein VMA12Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Accessory component of the proton-transporting vacuolar (V)-ATPase protein pump involved in intracellular iron homeostasis. In aerobic conditions, required for intracellular iron homeostasis, thus triggering the activity of Fe(2+) prolyl hydroxylase (PHD) enzymes, and leading to HIF1A hydroxylation and subsequent proteasomal degradation. Necessary for endolysosomal acidification and lysosomal degradation (PubMed:28296633). May be involved in Golgi homeostasis (PubMed:26833330). Binds 20(S)-hydro

LOCALIZAÇÃO

Cytoplasmic vesicle, COPI-coated vesicle membraneEndoplasmic reticulum-Golgi intermediate compartment membraneEndoplasmic reticulum membrane

MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2P

A form of congenital disorder of glycosylation, a genetically heterogeneous group of autosomal recessive, multisystem disorders caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. CDG2P is characterized by mild metabolic dysfunction, primarily affecting the liver. Psychomotor development is normal.

OUTRAS DOENÇAS (1)
TMEM199-CDG
HGNC:18085UniProt:Q8N511
SLC35A1CMP-sialic acid transporterDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Transports CMP-sialic acid from the cytosol into the Golgi apparatus, functioning as an antiporter that exchanges CMP-sialic acid for CMP (PubMed:12682060, PubMed:15576474, PubMed:23873973). Binds both CMP-sialic acid and free CMP, but has higher affinity for free CMP (By similarity). Also able to exchange CMP-sialic acid for AMP and UMP (PubMed:12682060). Also mediates the transport of CDP-ribitol (By similarity)

LOCALIZAÇÃO

Golgi apparatus membraneGolgi apparatus

VIAS BIOLÓGICAS (3)
Transport of nucleotide sugarsSialic acid metabolismMatriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 2F

CDGs are a family of severe inherited diseases caused by a defect in protein N-glycosylation. They are characterized by under-glycosylated serum proteins. These multisystem disorders present with a wide variety of clinical features, such as disorders of the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
59.8 TPM
Cervix Endocervix
54.0 TPM
Útero
52.9 TPM
Pulmão
51.4 TPM
Cervix Ectocervix
51.3 TPM
OUTRAS DOENÇAS (1)
SLC35A1-congenital disorder of glycosylation
HGNC:11021UniProt:P78382
SRD5A3Polyprenal reductaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays a key role in early steps of protein N-linked glycosylation by being involved in the conversion of polyprenol into dolichol (PubMed:20637498, PubMed:38821050). Acts as a polyprenal reductase that mediates the reduction of polyprenal into dolichal in a NADP-dependent mechanism (PubMed:38821050). Dolichols are required for the synthesis of dolichol-linked monosaccharides and the oligosaccharide precursor used for N-glycosylation (PubMed:20637498, PubMed:38821050). Also able to convert testos

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (2)
Synthesis of dolichyl-phosphateAndrogen biosynthesis
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1Q

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
14.3 TPM
Brain Spinal cord cervical c-1
12.7 TPM
Esôfago - Mucosa
12.4 TPM
Tecido adiposo
9.5 TPM
Vagina
9.2 TPM
OUTRAS DOENÇAS (2)
Kahrizi syndromeSRD5A3-congenital disorder of glycosylation
HGNC:25812UniProt:Q9H8P0
MPDU1Mannose-P-dolichol utilization defect 1 proteinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for normal utilization of mannose-dolichol phosphate (Dol-P-Man) in the synthesis of N-linked and O-linked oligosaccharides and GPI anchors

LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1F

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
64.0 TPM
Rim - Medula
52.5 TPM
Glândula adrenal
51.2 TPM
Tireoide
49.1 TPM
Baço
47.6 TPM
INTERAÇÕES PROTEICAS (5)
OUTRAS DOENÇAS (1)
MPDU1-congenital disorder of glycosylation
HGNC:7207UniProt:O75352

Variantes genéticas (ClinVar)

203 variantes patogênicas registradas no ClinVar.

🧬 COG6: NM_020751.3(COG6):c.686G>A (p.Trp229Ter) ()
🧬 COG6: NM_020751.3(COG6):c.1078C>T (p.Arg360Ter) ()
🧬 COG6: NM_020751.3(COG6):c.984_994del (p.Leu329fs) ()
🧬 COG6: GRCh37/hg19 13q13.1-21.32(chr13:33738980-68435696)x1 ()
🧬 COG6: NM_020751.3(COG6):c.695-8T>G ()
Ver todas no ClinVar

Vias biológicas (Reactome)

36 vias biológicas associadas aos genes desta condição.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
2Fase 22
·Pré-clínico2
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 4 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Alteração de glicosilação múltipla

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

2 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

0 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

🥉Melhor nível de evidência: Relato de caso
Timeline de publicações
0 papers (10 anos)
#1

Exogenous photoreceptor-specific N-glycosylated PROM1 rescues retinal degeneration in patient and mouse models.

Molecular therapy : the journal of the American Society of Gene Therapy2026 Feb 27

Human prominin-1 (PROM1) is broadly expressed across multiple tissues. However, its pathogenic variants cause an exclusive retina-related disorder, PROM1-associated inherited retinal dystrophy (PROM1-IRD). The mechanistic basis underlying this tissue-specific vulnerability remains unclear, and no approved targeted therapy is available. Here, we used urine cells, human induced pluripotent stem cells (hiPSCs), hiPSC-retinal pigment epithelial cells, retinal organoids (ROs), and Prom1-/- mice to address these challenges. During photoreceptor differentiation in ROs, PROM1 localized to the apical ciliary compartment and the outer segment (OS)-like structures, co-localizing with ARL13B and PRPH2, and displayed photoreceptor-enriched mRNA splicing isoforms and distinct N-glycosylation patterns. In models derived from an IRD patient harboring a homozygous PROM1 c.619G>T (p.E207×) mutation, PROM1 transcripts underwent both nonsense-mediated mRNA decay and nonsense-associated altered splicing, resulting in complete loss of PROM1 protein and severe disruption of OS-like structures. To restore PROM1 function, a photoreceptor-targeted AAV7m8-CRXp-hPROM1 vector was developed, which efficiently restored PROM1 expression and rescued OS-like structures in patient-derived ROs. In vivo, subretinal delivery of AAV8-CRXp-hPROM1 to Prom1-/- mice produced sustained, photoreceptor-targeted expression of human PROM1, significantly preserving OS morphology and improving visual function. Collectively, these findings implicate a molecular basis for retinal vulnerability to PROM1 variants and provide compelling preclinical evidence supporting adeno-associated-virus-mediated gene augmentation as a therapeutic approach for PROM1-IRD.

#2

Evolutionary lineage and host origin influence virulence and mammalian adaptation of H7N9 avian influenza viruses.

Poultry science2026 Feb 12

The H7N9 avian influenza virus (AIV) has posed a major global public health concern since its first detection in China in 2013. Transmitted among wild birds and poultry, this virus has crossed the species barrier to infect humans, causing severe respiratory disease and high mortality. Although the widespread use of H7 vaccines has markedly reduced human infections, the ongoing circulation and adaptive evolution of the virus in poultry remain a serious threat. In this study, we analyzed three highly pathogenic H7N9 isolates collected in China in 2022, representing two hemagglutinin (HA) gene evolutionary lineages: Group.y.2.3 (isolate 229-4, chicken origin; isolate 782-2, quail origin) and Group.y.2.4 (isolate 621, quail origin). Pathogenicity was compared through phylogenetic analysis, molecular characterization, and infection experiments in both avian and mammalian models. Group.y.2.3 isolates displayed stronger replication and pathogenicity in chickens and mice, with isolate 782-2 being the most virulent. The chicken-origin isolate 229-4 caused more severe weight loss and higher viral loads in the lungs of mice, indicating that host origin influences cross-species transmission potential. Molecular analyses revealed that all isolates possessed multiple basic cleavage sites and mutations linked to mammalian adaptation, including HA 186 V. Some isolates also harbored newly acquired glycosylation sites associated with immune evasion. Overall, our findings demonstrate that both genetic lineage and host origin shape the biological characteristics of H7N9 isolates. Group.y.2.3 isolates warrant priority in surveillance, providing critical insights for vaccine updates and risk assessment.

#3

Siamese Twins: The Multimodular Mechanisms of Golgi Maturation and Glycan Synthesis Are Coupled at Their Core.

Sub-cellular biochemistry2026

The Golgi apparatus functions as the central processing hub for proteins and lipids, orchestrating glycosylation, sorting, and secretion. Once viewed as a passive site of bulk enzyme recycling, the Golgi is now recognized as a highly dynamic, multimodular system in which intra-Golgi trafficking and glycan synthesis operate as tightly interdependent "Siamese twins." The classical cisternal maturation model, initially based on uniform COPI-mediated recycling, has evolved into the multimodular cisternal maturation (MCM) framework, revealing the coexistence of multiple, specialized recycling modules. Distinct sets of glycosyltransferases form coherent enzymatic modules, each maintained by dedicated retrograde pathways-some COPI-dependent, others COPI-independent-that ensure compartmental fidelity and enable differential regulation of glycan synthesis. These pathways are coordinated by adaptors, retainers, and lipid identity cues that collectively sustain Golgi polarity and adaptability to cellular and metabolic states. Disruption of this modular recycling logic leads to enzyme mislocalization, defective glycosylation, and disease, ranging from congenital disorders of glycosylation to oncogenic transformation. The transition from bulk to multimodular recycling thus redefines the Golgi as an integrated regulatory platform linking membrane trafficking to metabolic and signaling networks.

#4

GARP Complex in Golgi Physiology.

Sub-cellular biochemistry2026

The Golgi Associated Retrograde Protein (GARP) complex, a member of the Complexes Associated with Tethering Containing Helical Rods (CATCHR) family, is proposed to tether vesicles arriving from endosomes to the trans-Golgi network (TGN). Discovered nearly 25 years ago, this protein complex is important for sorting vacuolar hydrolases and recycling membrane proteins from the endosomal/prevacuolar compartment to the TGN; however, its exact function, molecular partners, and the nature of GARP-dependent trafficking intermediates remain understudied. GARP-dependent transport route is utilized by various plasma membrane recycling proteins, lysosomal hydrolase receptors, and pathogens, including toxins. Mutations in GARP subunits have been associated with multiple neurological disorders, although the precise mechanisms by which these mutations lead to these conditions remain unclear. This chapter reviews the current understanding of GARP's structure, function, interacting partners, mutations, and associated pathologies in both humans and model organisms.

#5

CSF-Compartmentalized Antibody Glycoprofiles in NMDAR Encephalitis Associate with Etiology and Functional Recovery.

Annals of neurology2026 Feb 18

To characterize Fc-glycosylation profiles in patients with anti-N-methyl-D-aspartate receptor encephalitis (NMDARe) and assess their association with antibody compartmentalization (cerebrospinal fluid [CSF] vs serum), disease triggers (viral, tumor-related or idiopathic), and 1-year outcomes. We analyzed immunoglobulin (Ig) G1 and IgG2/3 Fc-glycosylation by liquid chromatography-mass spectrometry in paired serum/CSF samples from 50 age- and sex-matched patients with NMDARe identified in IDIBAPS/Hospital Clinic of Barcelona database and the Spanish study on herpes encephalitis. Patients were classified by disease trigger as post-herpetic, tumor-related, or idiopathic. One-year outcomes were defined as good (modified Rankin Scale [mRS] ≤2) or poor (≥3). Fc glycoprofiles were quantified for fucosylation, sialylation, galactosylation, and bisecting N-acetylglucosamination. Across IgG subclasses (IgG1-3), CSF antibodies showed significantly reduced sialylation and galactosylation compared to serum (p < 0.0001), indicating a pro-inflammatory compartmentalized response within the central nervous system. These inflammatory Fc-glycoforms were predominant in post-herpetic cases of NMDARe (p < 0.01) compared to tumor-related and idiopathic forms, suggesting that viral-induced NMDAR may alter antibody Fc-glycosylation via B-cell glycosylation pathway modulation. Furthermore, reduced sialylation, galactosylation and fucosylation in CSF and serum were associated with poor 1-year outcomes (p < 0.05), suggesting that compartmentalized inflammation and enhanced innate immune activation, including natural killer (NK) cell-mediated cytotoxicity driven by afucosylated antibodies, might contribute to neurological dysfunction. In NMDARe, CSF Fc-glycosylation profiles are both compartment- and trigger-specific. Because glycan signatures shape innate immune interactions (e.g., with NK cells), these findings highlight distinct pathogenic mechanisms and support Fc-glycosylation profiling as a potential prognostic biomarker. ANN NEUROL 2026.

Publicações recentes

Ver todas no PubMed

📚 EuropePMCmostrando 199

2026

Comparative Association of Basal and Basal-Prandial Insulin Regimens on Remnant Cholesterol and Lipid Profiles in Patients with Type 2 Diabetes Mellitus.

Diabetes, metabolic syndrome and obesity : targets and therapy
2026

bZIP63.5 Regulates a Zinc-Finger Mediated Detoxification Network in Trichoderma Harzianum for Enhanced Biocontrol of Alternaria alternata.

Microbial biotechnology
2026

Alport syndrome complicated with IgA nephropathy: a case report.

Frontiers in medicine
2026

ALG8-Driven Metabolic Reprogramming in Polycystic Kidney Disease: A Systematic Synthesis of Evidence Linking Glycosylation Defects to Metabolic Signaling.

IUBMB life
2026

Sex as a predictor and moderator of psychosocial determinants of cardiometabolic risks for Métis People in Canada.

Frontiers in stroke
2026

High-throughput simultaneous quantification of glycopeptides and phosphopeptides enabled by 12-plex DiLeu isobaric tags and dual-functional Titanium(IV)-IMAC material.

Analytica chimica acta
2026

Exogenous photoreceptor-specific N-glycosylated PROM1 rescues retinal degeneration in patient and mouse models.

Molecular therapy : the journal of the American Society of Gene Therapy
2026

Evolutionary lineage and host origin influence virulence and mammalian adaptation of H7N9 avian influenza viruses.

Poultry science
2026

A founder variant in Tunisian PMM2-CDG patients: An integrated clinical, radiological, biochemical, and genetic study.

Molecular genetics and metabolism
2026

Siamese Twins: The Multimodular Mechanisms of Golgi Maturation and Glycan Synthesis Are Coupled at Their Core.

Sub-cellular biochemistry
2026

GARP Complex in Golgi Physiology.

Sub-cellular biochemistry
2026

CSF-Compartmentalized Antibody Glycoprofiles in NMDAR Encephalitis Associate with Etiology and Functional Recovery.

Annals of neurology
2026

Sialylation in the nervous system: Functions and mechanisms.

The Journal of biological chemistry
2026

Small Molecules as Modulators to Prevent Mucin Aggregation via Delaying Liquid-to-Solid Phase Transition.

The journal of physical chemistry letters
2026

Multi-Omics Analysis of Morbid Obesity Using a Patented Unsupervised Machine Learning Platform: Genomic, Biochemical, and Glycan Insights.

International journal of molecular sciences
2026

Sweet Surprises: Decoding Tumor-Associated Glycosylation in Cancer Progression and Therapeutic Potential.

Cells
2026

Methicillin-resistant Staphylococcus aureus has phenotypic variation in mecA expression that alters antibiotic sensitivity.

Antimicrobial agents and chemotherapy
2026

Evaluation of Speech Recognition in Noise in Patients with Type 2 Diabetes Mellitus in a Tertiary Care Hospital: A Cross-Sectional Analytical Study.

Audiology &amp; neuro-otology
2026

Apolipoprotein D, a Novel Ligand for CD36, Is Essential for Blood-Brain Barrier Integrity.

Circulation
2026

Metabolic indexes of obesity in major depressive disorders in different age groups.

Medicine
2026

Molecular Signatures of Preeclampsia: The Role of Post-Translational Protein Modifications.

Comprehensive Physiology
2026

FAPα+ Macrophages Orchestrate Immune Evasion in Multiple Myeloma by Dual Regulation of PD-L1 and T Cell Senescence.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
2026

Perspectives on intrinsic articular cartilage interfaces.

Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft
2025

Exploring the Role of the Extracellular Matrix in Disease and Aging.

Juntendo medical journal
2026

Relevance analysis of N-glycan variations in C2C12 cells and mouse serum under simulated microgravity using a quaternary phosphonium hydrazide labeling strategy-based mass spectrometry quantitation approach.

Analytical and bioanalytical chemistry
2026

Serum soluble ASGR1 concentration is elevated in patients with metabolic dysfunction-associated steatotic liver disease and is associated with adiponectin.

BMJ open diabetes research &amp; care
2025

Spectrum of Cardiac Complications in Diabetic Patients in Rural Uttar Pradesh, India: A Hospital-Based Study.

Cureus
2026

GMPPB-CDG Results in Lysosomal Dysfunction and Acid Alpha-Glucosidase Deficiency.

Journal of inherited metabolic disease
2026

PMM2-CDG and the Role of Liver Transplantation as a Long-Term Solution: A Case Report.

Pediatric transplantation
2026

Is Toxoplasma gondii-secreted Protein With an Altered Thrombospondin Repeat (TgSPATR) a Potential Candidate for Immunisation? An Immunoinformatics-Based Analysis.

Veterinary medicine and science
2026

Oligosaccharyltransferase (OST) complex inhibition effectively treats rodent and human prions.

PLoS pathogens
2026

Diagnostic Potential of Tn-MUC1 in Breast Cancer: A Novel Immunohistochemical Marker Reflecting Tumor Progression.

Laboratory investigation; a journal of technical methods and pathology
2026

Structure and multiple functions of von Willebrand factor.

Haematologica
2026

Streptomycin mitigates methylglyoxal-induced carbonyl stress through its antiglycation activity: A drug-repurposing approach for carbonyl stress-related disorder.

Chemico-biological interactions
2025

Factors influencing nutrition literacy in patients of type 2 diabetes mellitus: a cross-sectional study.

Frontiers in nutrition
2026

Glycosylation of GETV E2 promotes pathogenesis in animal models.

Proceedings of the National Academy of Sciences of the United States of America
2025

HCV Genotype Distribution and Molecular Characteristics of HCV Core Domain I in Persons Living with HIV and HCV from Yunnan Province, China.

AIDS research and human retroviruses
2025

Antibody glycosylation in neuroimmune diseases.

Journal of translational medicine
2025

Clinical and genetic characterization of congenital disorders of glycosylation in 20 Chinese patients.

Orphanet journal of rare diseases
2025

[Inhibition of O-GlcNAc transferase alleviates liver pathological changes in spontaneously obese mice].

Sheng li xue bao : [Acta physiologica Sinica]
2025

ATM interaction with GRP94 modulates oncogenic receptor expression and signaling and microglial activation.

Proceedings of the National Academy of Sciences of the United States of America
2025

mRNA-LNP vaccine encoding CDV hemagglutinin confers effective protection in raccoon dogs.

NPJ vaccines
2026

Phytochemicals from Achillea millefolium target NAFLD and NASH: A network pharmacology integrated bioinformatics and molecular docking investigation.

Computational biology and chemistry
2026

Interferon-stimulated gene GALNT2 restricts respiratory virus infections.

Nature microbiology
2025

RNF13 is a previously undescribed interactor of iduronate 2-sulfatase that modifies its glycosylation and maturation.

The FEBS journal
2025

GlySitePred: Identification of Glycation Modification Sites Based on Deep Feature Fusion and NCR-CC Sampling Technology.

Journal of chemical information and modeling
2026

Profiling Associations Between IGHG-FCGR Ligand-Receptor Interactions and Disease Progression From Stage 1 and 2 to Stage 3 Type 1 Diabetes.

Diabetes
2025

Identification and characterization of Porphyromonas gingivalis TonB.

bioRxiv : the preprint server for biology
2025

Epididymal epithelial cells facilitate NEU1 loading to modulate sperm α-2,6 sialylation, enhance maturation and motility.

Cellular and molecular life sciences : CMLS
2025

A Survey of Opsin Localization, Glycosylation, and Light/Chromophore Influence on Degeneration in 26 Rhodopsin-Associated RP Models.

Investigative ophthalmology &amp; visual science
2026

Extended verification of an automated MALDI-TOF mass spectrometry system for high throughput serum M-protein measurement.

Clinical chemistry and laboratory medicine
2025

In Vitro Evaluation of Sugar-Conjugated Thienopyrimidinone Derivatives with Possible Neuroprotective and Antioxidant Effects.

International journal of molecular sciences
2025

The Emerging Role of Sialic Acids in Obesity and Diabetes: Molecular Mechanisms and Therapeutic Perspectives.

Biomolecules
2025

Genome landscape of the universal stress protein gene family in lettuce and expression profile in response to heat stress.

BMC plant biology
2025

Atomic structure and in situ visualization of native PMEL lamellae in melanosomes.

Nature communications
2025

Clinical and functional characterization of a novel heterozygous mutation c.473T > A (p.Leu158Gln) in the SERPINC1 gene causing recurrent arteriovenous thrombophilia.

Thrombosis journal
2025

Multivariate analysis of glycogenes reveals coordinated regulation of immunoglobulin glycosylation in an immortalized human B cell system.

bioRxiv : the preprint server for biology
2025

Comparative Study of Glycemic Control and Treatment Satisfaction in Patients With Type 1 Diabetes on Sensor-Augmented Insulin Pump, Insulin Pump, and Multiple Daily Insulin Injections: A Cross-Sectional Study.

Cureus
2026

Clinical Profile of Psoriasis Patients With Comorbid Fatty Liver and Risk Factors for Advanced Liver Fibrosis in Those With Metabolic Dysfunction-Associated Steatotic Liver Disease.

The Journal of dermatology
2026

Nanoscale Mapping of the Subcellular Glycosylation Landscape.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
2025

Insights into the multifunctionality of viral glycoproteins F and HN in the lifecycle and pathogenesis of Newcastle disease virus: a systematic review.

Veterinary research
2025

Congenital disorder of glycosylation type IIb in an infant with developmental and epileptic encephalopathy.

BMJ case reports
2025

In vitro cell model to dilucidate the underlying molecular mechanism associated with ophthalmic manifestation of congenital disorders of glycosylation: studying an ALG2-CDG patient.

Frontiers in genetics
2025

MS1-96 induces HIP1R-dependent PD-L1 degradation and promotes antitumor immunity in colorectal cancer.

Acta pharmacologica Sinica
2025

Elevated fasting glucose levels associated with H. pylori acute gastritis: an observational study.

Journal of medicine and life
2025

Glycemic, renal, and graft outcomes with dulaglutide versus multiple daily insulin therapy after kidney transplantation in type 2 diabetes.

Diabetes research and clinical practice
2025

Candidate genes at the Rmi1 locus for resistance to Meloidogyne incognita in soybean.

TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik
2025

Campylobacter hepaticus Transcriptomics Identified Genes Involved in Spotty Liver Disease (SLD) Pathogenesis.

Pathogens (Basel, Switzerland)
2025

Pro-Inflammatory Protein PSCA Is Upregulated in Neurological Diseases and Targets β2-Subunit-Containing nAChRs.

Biomolecules
2025

Quantitative Targeted Analysis of Antibody Fc Glycosylation by Glyco-MRM.

Journal of proteome research
2025

Modulation of OGG1 enzymatic activity by the cellular machinery - have all the boxes been ticked?

DNA repair
2025

Isolation and molecular characterization of subgroup J avian leukosis virus in native chicken breeds of China during 2022-2025.

Frontiers in microbiology
2025

Decoding Glycosylation in Neurodegenerative Diseases: Mechanistic Insights and Therapeutic Opportunities.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2025

Plasma N-Glycan Profiling Enhances Diagnostic Precision in Multiple Sclerosis, AQP4-Ab NMOSD, and MOGAD.

Neurology(R) neuroimmunology &amp; neuroinflammation
2025

Subgrouping patients with type 2 diabetes using behavioural and clinical factors: a cross-sectional study in a hospital-based setting in Thailand.

BMJ open
2025

Association of Serum Thyroid Profile and Glycated Hemoglobin Levels in Diabetic Patients: A Cross-Sectional Study.

Cureus
2025

The Importance of N- and O-Glycosylation of Brain Cell Surface Glycoproteins.

Glycobiology
2025

2B4/CD244 Signaling in Immune Regulation and Its Role in Infection, Cancer, and Immune Tolerance.

ImmunoTargets and therapy
2025

Molecular dynamics insights into glycosaminoglycan effects on the extracellular domains of syndecan 2 and 4 dimers.

Carbohydrate research
2025

Abnormal Biochemical Parameters of Macro- and Microvascular Complications in Diabetic Patients at the Bafoussam Regional Hospital of the West Region, Cameroon.

Cureus
2025

A new formula for evaluating culprit lesion characteristics in STEMI patients based on baseline.

American heart journal plus : cardiology research and practice
2025

Abnormal O-glycan sialylation in the mPFC contributes to depressive-like behaviors in male mice.

Science advances
2025

Comprehensive and Site-Specific Characterization of Protein N-Glycosylation in AD Samples Reveals Its Potential Roles in Protein Aggregation and Synaptic Dysfunction.

Analytical chemistry
2025

Pharmacological Diversity of Flavonoids and Their Clinical Application Prospects in Neurological Disorders.

Phytotherapy research : PTR
2026

CD19 structure, expression, and signaling: From basic mechanisms to therapeutic targeting.

Advances in biological regulation
2025

Extracellular matrix protein 1 in cancer: multifaceted roles in tumor progression, prognosis, and therapeutic targeting.

Archives of pharmacal research
2025

Glycosylation in neuroinflammation: mechanisms, implications, and therapeutic strategies for neurodegenerative diseases.

Translational neurodegeneration
2025

Restoration of glucose metabolic homeostasis for treating CNS diseases: mechanistic insights and potential clinical prospect.

Free radical biology &amp; medicine
2025

The Transformative Role of Mass Spectrometry in Diagnosing and Monitoring Monoclonal Gammopathies and Plasma Cell Disorders.

The journal of applied laboratory medicine
2025

The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics.

Trends in pharmacological sciences
2025

Naturally acquired promoter variation influences Streptococcus pneumoniae infection outcomes.

Cell host &amp; microbe
2025

Epidemiological dynamics of influenza B virus across multiple seasons in Kenya and Uganda inferred from sequence data, 2010-2021.

BMC infectious diseases
2025

Investigation of the Clinical and Genetic Spectrum of PMM2-CDG: Insights from a Family with a Novel Variant and Previous Studies.

Archives of Iranian medicine
2025

A Phase II Random, Double-Blind, Placebo-Controlled Study of the Safety and Immunogenicity of a Recombinant G Protein-Based Respiratory Syncytial Virus Vaccine in Healthy Older Adults.

Vaccines
2025

The β-1,4 GalT-V Interactome-Potential Therapeutic Targets and a Network of Pathways Driving Cancer and Cardiovascular and Inflammatory Diseases.

International journal of molecular sciences
2025

Bi-Allelic Loss-of-Function Variant in MAN1B1 Cause Rafiq Syndrome and Developmental Delay.

International journal of molecular sciences
2025

Epidemiology and Genetic Diversity of Human Metapneumovirus in Patients with Severe Acute Respiratory Infection from 2023 to 2024 in Ningxia, China.

Diseases (Basel, Switzerland)
2025

Development and internal validation of a machine learning algorithm for the risk of type 2 diabetes mellitus in children with obesity.

Frontiers in endocrinology
2025

Development of avian influenza A(H5) virus datasets for Nextclade enables rapid and accurate clade assignment.

Virus evolution
2025

PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study.

Annals of hematology
2025

Predictable Modulation of a Spontaneous Post-translational Modification in Living Cells.

Angewandte Chemie (International ed. in English)
2025

Integrating bioinformatics and machine learning to elucidate the role of protein glycosylation-related genes in the pathogenesis of diabetic kidney disease.

PloS one
2025

Novel pathogenic MAN2B2 variants cause systemic lupus erythematosus and dysregulated glycosylation.

Clinical immunology (Orlando, Fla.)
2025

Intriguing role of the Golgi apparatus in astrocyte function: Implications for disorders.

Neural regeneration research
2026

Functional Characterization of Two Novel Biallelic PIGV Variants in a Patient With Myoclonic Seizures and Elevated Alkaline Phosphatase: A Case Report.

American journal of medical genetics. Part A
2025

Laboratory diagnosis of congenital and acquired coagulopathies, including challenging-to-diagnose rare bleeding disorders.

Pathology
2025

Serum Vitamin B12 Level in Children with Type 1 Diabetes.

Journal of Nepal Health Research Council
2025

Phosphomannomutase 2-congenital disorder of glycosylation: exploring the role of N-glycosylation on the endocrine axes.

Frontiers in endocrinology
2025

Association between cardiovascular disease and peripheral arterial disease implications for patient safety.

BMC cardiovascular disorders
2025

Glycemic, lipid, anthropometric and body composition responses to two Mango varieties versus white bread in people with type 2 diabetes: an 8-week randomised controlled trial.

Journal of diabetes and metabolic disorders
2025

Commiphora leptophloeos leaf and bark extracts modulate OxInflammation through TLR4/ NF-κB/ Nrf2 pathways.

Journal of ethnopharmacology
2025

Analysis of gastric electrical rhythm in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus.

World journal of hepatology
2025

Serum N-Glycan Signatures as Potential Biomarkers for the Detection and Monitoring of IgG4-Related Disease.

Journal of proteome research
2025

The XEC Variant: Genomic Evolution, Immune Evasion, and Public Health Implications.

Viruses
2025

Two novel cases with PIGQ-CDG: expansion of the genotype-phenotype spectrum and evaluation of GestaltMatcher as a diagnostic tool.

Frontiers in genetics
2025

Enzymatic synthesis and mechanistic insights into the hepatoprotective effects of α-monoglucosyl rutin against cyclophosphamide-induced liver injury: a multi-omics approach.

International immunopharmacology
2025

A Glycoproteome Data Mining Strategy for Characterizing Structural Features of Altered Glycans with Thymic Involution.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
2025

Persistent Neutropenia and Atopy in an Adolescent: A Subtle Presentation of Phosphoglucomutase 3 Deficiency.

Cureus
2025

Predictive value of Glycosylated Fibronectin (GlyFn)/Placenta Growth Factor (PlGF) ratio for high-risk pregnancies: a cohort study.

BMC pregnancy and childbirth
2025

The biology of interleukin-6 family cytokines is regulated by glycosylation.

The Biochemical journal
2025

Irisin: Emerging Therapeutic Targets for Cognitive Impairment-Related Diseases.

Expert reviews in molecular medicine
2025

B4GALT3 as a Key Glycosyltransferase Gene in Multiple Myeloma Progression: Insights From Bioinformatics, Machine Learning, and Experimental Validation.

Molecular carcinogenesis
2025

Insights into the detection of AMPA cross-reactivity: comparing cyclic peptide- to protein-based assays.

Arthritis research &amp; therapy
2025

A mass spectrometry-based assay for mouse IgG N-glycan screening in biofluids.

Analytical and bioanalytical chemistry
2025

Ultradeep N-glycoproteome atlas of mouse reveals spatiotemporal signatures of brain aging and neurodegenerative diseases.

Nature communications
2025

Multiple Exposures of Plasma to Nanoparticles: A Novel Tool to Personalize Biomolecular Coronas and Fractionate Fluids.

Analytical chemistry
2026

Aryl hydrocarbon receptor impairs HK2-controlled flux of the hexosamine biosynthesis pathway to suppress NETosis in an N-glycosylation-dependent manner.

Journal of advanced research
2025

A biparatopic HER2-targeting ADC constructed via site-specific glycan conjugation exhibits superior stability, safety, and efficacy.

RSC chemical biology
2025

Parkinson's disease-linked Kir4.2 mutation R28C leads to loss of ion channel function.

The Journal of physiology
2025

Multiple Mechanisms of HIV-1 Resistance to PGT135 in a Chinese Subtype B' Slow Progressor.

Pathogens (Basel, Switzerland)
2025

Genetic characterization and pathogenicity analysis of three porcine epidemic diarrhea virus strains isolated from North China.

Veterinary research
2025

Accurate Diagnosis of Colorectal Cancer Using a Combination of Lectin-Induced Recombinase Polymerase Amplification and CRISPR/Cas12a Assay on a Point-of-Care Testing Platform with Deep Learning Assistant.

Analytical chemistry
2025

Glycoside hydrolase 28 family protein RsPG1 from Rhizoctonia solani motivates immune response to pathogen attack in different host plants.

International journal of biological macromolecules
2025

Study on the Mechanism of Dihydromyricetin in Alleviating Depressive-Like Behavior in Rats Based on Network Pharmacology.

Neurochemical research
2025

Study on the correlation between abnormal bone metabolism and cognitive impairment in type 2 diabetes mellitus.

Frontiers in medicine
2025

Developing and validating a predictive model for all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease.

Diabetology &amp; metabolic syndrome
2025

FUT8 Is a Critical Driver of Prostate Tumour Growth and Can Be Targeted Using Fucosylation Inhibitors.

Cancer medicine
2025

GALNT14 deficiency: connecting multiple links in the IgA nephropathy pathogenetic chain.

The Journal of clinical investigation
2025

Mechanisms of action of Fucus vesiculosus-derived fucoidan on improving dyslipidemia in New Zealand rabbits fed a high-fat diet.

International journal of biological macromolecules
2025

ER stress disrupts insulin release in murine models of type 2 diabetes by impairing retromer action and constitutive secretion.

Cell reports
2025

Irisin restrains neuroinflammation in mouse experimental autoimmune encephalomyelitis via regulating microglia activation.

Frontiers in pharmacology
2025

Complex Metabolomic Changes in a Combined Defect of Glycosylation and Oxidative Phosphorylation in a Patient with Pathogenic Variants in PGM1 and NDUFA13.

Cells
2025

Further elucidation of GMPPB as a risk gene for depression through integrative multi-omics analyses.

Journal of affective disorders
2025

Evolution and adaptation of dengue virus in response to high-temperature passaging in mosquito cells.

Virus evolution
2025

ɑ1,3-mannosyltransferase promotes the malignant progression of bladder cancer through activating TNF signaling pathway.

European journal of medical research
2025

Aminooxy Biotin-Based Characterization of the Surfaceome of Chondrogenic Cells.

Methods in molecular biology (Clifton, N.J.)
2025

Associations of Skin Autofluorescence with Diabetic Kidney Disease in Type 2 Diabetes.

Biomedicines
2025

Elevated Fab glycosylation of autoantibodies maintained during B cell depletion therapy.

Scientific reports
2025

Neuroprotective roles of SGLT2 and DPP4 inhibitors: Modulating ketone metabolism and suppressing NLRP3 inflammasome in T2D induced Alzheimer's disease.

Experimental neurology
2025

Real-world clinical utility of a multi-protein, blood-based biomarker assay for disease activity assessments in multiple sclerosis.

Multiple sclerosis journal - experimental, translational and clinical
2026

Treatment of acute myeloid leukemia models by targeting a cell surface RNA-binding protein.

Nature biotechnology
2025

Characteristics of type 2 diabetes patients with overt cardiovascular diseases in Malaysia: the real-world evidence from the National Diabetes Registry.

BMC research notes
2025

Glycosylphosphatidylinositol Biosynthesis Defect Due To Novel Biallelic Pathogenic Variants in PIGW.

Pediatric neurology
2025

Prevalence and determinants of erectile dysfunction among male type 2 diabetes mellitus patients with chronic kidney disease: a cross-sectional study.

Translational andrology and urology
2025

New insights into phytochemicals via protein glycosylation focused on aging and diabetes.

Phytomedicine : international journal of phytotherapy and phytopharmacology
2025

LGALS3BP antibody-drug conjugate enhances tumor-infiltrating lymphocytes and synergizes with immunotherapy to restrain neuroblastoma growth.

Journal of translational medicine
2025

COG6-related prenatal phenotype (CDG2L): Clinico-pathological report and review of the literature.

Molecular genetics &amp; genomic medicine
2025

Diagnostic Utility of Next-Generation Sequencing-based CNV Analysis in Eleven Patients with Peters-Plus Syndrome: A Single-Center Experience.

Journal of clinical research in pediatric endocrinology
2025

Deciphering N-Glycosylation Dynamics of Serum Monoclonal Immunoglobulins in Multiple Myeloma via EThcD-sceHCD-MS/MS.

Journal of proteome research
2025

Integration of RNAseq transcriptomics and N-glycomics reveal biosynthetic pathways and predict structure-specific N-glycan expression.

Chemical science
2025

Lysyl hydroxylase 2 glucosylates collagen VI to drive lung cancer progression.

The Journal of clinical investigation
2025

The Inner Nuclear Layer in Pediatric Multiple Sclerosis.

Neurology(R) neuroimmunology &amp; neuroinflammation
2025

Multi-omic biomarkers associated with multiple sclerosis: from Mendelian randomization to drug prediction.

Scientific reports
2025

Deciphering distinct spatial alterations in N-glycan expression profiles in the spinal cord and brain of male rats in a neuropathic pain model.

Cellular &amp; molecular biology letters
2025

Towards a Universal Translator: Decoding the PTMs That Regulate Orthoflavivirus Infection.

Viruses
2025

High-Density Lipoprotein in Patients with Diabetic Kidney Disease: Friend or Foe?

International journal of molecular sciences
2025

Exploring the relationship between sepsis and Golgi apparatus dysfunction: bioinformatics insights and diagnostic marker discovery.

Frontiers in genetics
2025

Synergistic effects of mutation and glycosylation on disease progression.

Frontiers in molecular biosciences
2025

Mass Spectrometry-Based Proteomics in Clinical Diagnosis of Amyloidosis and Multiple Myeloma: A Review (2012-2024).

Journal of mass spectrometry : JMS
2025

Serum Ferritin Levels in Pregnancy and Their Association with Gestational Diabetes Mellitus: A Prospective Longitudinal Study.

Diabetes, metabolic syndrome and obesity : targets and therapy
2025

Neurite orientation dispersion and density imaging in myelin oligodendrocyte glycoprotein antibody-associated disease and neuromyelitis optica spectrum disorders.

Multiple sclerosis and related disorders
2025

Biochemical testing for congenital disorders of glycosylation: A technical standard of the American College of Medical Genetics and Genomics (ACMG).

Genetics in medicine : official journal of the American College of Medical Genetics
2025

Inhibition of high glucose-induced cardiac fibroblast activation: an effective treatment for diabetic cardiomyopathy using Chinese herbal medicine.

Frontiers in pharmacology
2025

O-GlcNAc modification differentially regulates microtubule binding and pathological conformations of tau isoforms in vitro.

The Journal of biological chemistry
2025

Arv1; a "Mover and Shaker" of Subcellular Lipids.

Contact (Thousand Oaks (Ventura County, Calif.))
2025

Phylogenetic and molecular analysis of hemagglutinin gene and Fsp-coding region of canine distemper virus: Insight into novel vaccine development.

Comparative immunology, microbiology and infectious diseases
2025

Functional Characterization and In Silico Prediction Tools Improve the Pathogenicity Prediction of Novel Bile Acid Transporter Variants.

Clinical genetics
2025

Elevated Fasting C-Peptide Levels Correlate with Increased 10-Year Risk of Atherosclerotic Cardiovascular Disease in Newly Diagnosed Type 2 Diabetes Patients.

Diabetes, metabolic syndrome and obesity : targets and therapy
2025

Assessing the role of Berberine as an inhibitor of advanced glycation end products (AGEs) formation using in vitro and molecular interaction studies.

Archives of biochemistry and biophysics
2025

The effects of regular exercise on cognitive and cardiometabolic health in testicular cancer survivors subjected to platinum-based chemotherapy.

Andrology
2025

Glycan profiling of multiple sclerosis oligoclonal bands with MALDI-TOF.

Analytical methods : advancing methods and applications
2025

Aldolase B Deficient Mice Are Characterized by Hepatic Nucleotide Sugar Abnormalities.

Journal of inherited metabolic disease
2024

Novel mTORC2/HSPB4 Interaction: Role and Regulation of HSPB4 T148 Phosphorylation.

Cells
2024

A quantitative multi-parameter mapping protocol standardized for clinical research in multiple sclerosis.

Scientific reports
2025

Defective glycosylation and ELFN1 binding of mGluR6 congenital stationary night blindness mutants.

Life science alliance
2025

The evolution of hemagglutinin-158 and neuraminidase-88 glycosylation sites modulates antigenicity and pathogenicity of clade 2.3.2.1 H5N1 avian influenza viruses.

Veterinary microbiology
2025

CHIME Syndrome in a Child With Homozygous PIGL p.Leu167Pro Variant.

American journal of medical genetics. Part A
2024

SLC41A1 overexpression correlates with immune cell infiltration in HCC and promotes its malignant progression.

International journal of medical sciences
2025

Interpretable time-series neural turing machine for prognostic prediction of patients with type 2 diabetes in physician-pharmacist collaborative clinics.

International journal of medical informatics
2024

Neuroinflammation and glycosylation-related cerebrospinal fluid proteins for predicting functional decline in amyotrophic lateral sclerosis: a proteomic study.

Frontiers in neurology
2024

The role of protein O-GlcNAcylation in diabetic cardiomyopathy.

Biochemical Society transactions
2024

Towards Understanding the Role of the Glycosylation of Proteins Present in Extracellular Vesicles in Urinary Tract Diseases: Contributions to Cancer and Beyond.

Molecules (Basel, Switzerland)
2024

Predicting Structural Consequences of Antibody Light Chain N-Glycosylation in AL Amyloidosis.

Pharmaceuticals (Basel, Switzerland)
2024

Molecular characterization of human respiratory syncytial virus strains circulating among hospitalized children in Jordan.

BMC infectious diseases
2025

Single-cell transcriptome analysis identifies subclusters and signature with N-glycosylation in endometrial cancer.

Clinical &amp; translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
2024

Immunoglobulin A Antibodies: From Protection to Harmful Roles.

Immunological reviews
2024

Time-course RNA sequencing reveals high similarity in mRNAome between hepatic stellate cells activated by agalactosyl IgG and TGF-β1.

Functional &amp; integrative genomics
2024

Causality of Blood Metabolites on Proliferative Diabetic Retinopathy: Insights From a Genetic Perspective.

Journal of diabetes research
2024

Altered Spike Immunoglobulin G Fc N-Linked Glycans Are Associated With Hyperinflammatory State in Adult Coronavirus Disease 2019 and Multisystem Inflammatory Syndrome in Children.

Open forum infectious diseases

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Alteração de glicosilação múltipla.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Alteração de glicosilação múltipla

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Exogenous photoreceptor-specific N-glycosylated PROM1 rescues retinal degeneration in patient and mouse models.
    Molecular therapy : the journal of the American Society of Gene Therapy· 2026· PMID 41764073mais citado
  2. Evolutionary lineage and host origin influence virulence and mammalian adaptation of H7N9 avian influenza viruses.
    Poultry science· 2026· PMID 41747464mais citado
  3. Siamese Twins: The Multimodular Mechanisms of Golgi Maturation and Glycan Synthesis Are Coupled at Their Core.
    Sub-cellular biochemistry· 2026· PMID 41718979mais citado
  4. GARP Complex in Golgi Physiology.
    Sub-cellular biochemistry· 2026· PMID 41718975mais citado
  5. CSF-Compartmentalized Antibody Glycoprofiles in NMDAR Encephalitis Associate with Etiology and Functional Recovery.
    Annals of neurology· 2026· PMID 41708521mais citado
  6. Genetic and non-genetic factors influencing phenotypic variability in neurofibromatosis type 1.
    Orphanet J Rare Dis· 2026· PMID 41987183recente
  7. Real-time breath metabolomics as catalyst for personalized lung cancer diagnostics: prospective matched case-control trial (LUCAbreath).
    Transl Lung Cancer Res· 2026· PMID 41982695recente
  8. The mutational burden in os odontoideum patients.
    Orphanet J Rare Dis· 2026· PMID 41981692recente
  9. European Reference Networks - a flagship activity of the EU in the field of rare and complex diseases: from 2017 to 2025.
    Orphanet J Rare Dis· 2026· PMID 41981625recente
  10. Clinical characteristics and long-term prognosis of anti-MDA5-positive dermatomyositis: a comparative study across age groups.
    Orphanet J Rare Dis· 2026· PMID 41965859recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:309526(Orphanet)
  2. MONDO:0017749(MONDO)
  3. GARD:21343(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q55787325(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Alteração de glicosilação múltipla
Compêndio · Raras BR

Alteração de glicosilação múltipla

ORPHA:309526 · MONDO:0017749
CID-11
MedGen
UMLS
C5681039
Wikidata
Evidência
🥉 Relato de caso
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades